Blurbs

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and Treace Medical Concepts (TMCI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals (RCKTResearch Report) and Treace Medical Concepts (TMCIResearch Report) with bullish sentiments.

Rocket Pharmaceuticals (RCKT)

In a report released today, Gil Blum from Needham maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $62.00. The company’s shares closed last Tuesday at $13.69.

According to TipRanks.com, Blum ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.4% and a 27.1% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rocket Pharmaceuticals with a $46.25 average price target, which is a 237.6% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $62.00 price target.

See the top stocks recommended by analysts >>

Treace Medical Concepts (TMCI)

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Treace Medical Concepts, with a price target of $28.00. The company’s shares closed last Tuesday at $23.55.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 6.3% and a 42.3% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Zimmer Biomet Holdings, and Organogenesis Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Treace Medical Concepts with a $25.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RCKT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos